GlassScriptPhysician profile
Falguni C Patel
NPI 1710151725
$3,790.28
in general payments reported to CMS, 2019-2025
23 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $143 · 2021: $336 · 2022: $673 · 2023: $686 · 2024: $940 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $976.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $418.54 | 2019-2025 | |
| Amgen INC. | $390.59 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $326.69 | 2019-2025 | |
| Astellas Pharma US INC | $254.19 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $240.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Lilly USA, LLC | $234.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $220.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $134.51 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $112.36 | 2019-2022 | |
| Abbott Laboratories | $106.54 | 2019-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $55.10 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.33 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.55 | 2019-2023 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.32 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $36.31 | 2022-2023 | Rexulti |
| Lundbeck LLC | $33.77 | 2023-2024 | Rexulti |
| Ibsa Pharma INC. | $23.63 | 2019 | |
| Sanofi Pasteur INC. | $17.17 | 2020 | |
| Allergan, INC. | $12.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.51 | 2019 | |
| Vertos Medical, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Falguni Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.